ClearPoint Neuro, Inc. (CLPT)
$
13.59
-0.52 (-3.83%)
Key metrics
Financial statements
Free cash flow per share
-0.4863
Market cap
404.3 Million
Price to sales ratio
11.7756
Debt to equity
2.2518
Current ratio
6.3739
Income quality
0.5656
Average inventory
6.4 Million
ROE
-1.1428
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States, developing and commercializing platforms for minimally invasive surgical procedures in the brain, with the guidance of direct and intra-procedural magnetic resonance imaging (MRI). The company's offerings include the ClearPoint system, which facilitates the insertion of deep brain stimulation electrodes and biopsy needles, as well as the infusion of pharmaceuticals and laser catheters into the brain, alongside the ClearPoint Neuro Navigation System, an MRI suite. Despite its innovative contributions, the company reported a net loss of -$18,914,000.00 indicating challenges in its operations. Additionally, the company incurred depreciation and amortization expenses of $1,903,000.00 reflecting the wear and tear of its assets. The EBITDA is -$17,843,000.00 a key indicator of the company's operational profitability, while the EBITDA ratio is -$0.57 highlighting the company's operational efficiency. The total costs and expenses for the company stand at $51,136,000.00 reflecting its overall spending. Established in 1998 and originally known as MRI Interventions, Inc., the company changed its name to ClearPoint Neuro, Inc. in February 2020 and is headquartered in Solana Beach, California. In the financial landscape, ClearPoint Neuro, Inc. presents itself as an affordable investment opportunity, with the stock priced at $11.20 making it suitable for budget-conscious investors. The stock demonstrates a low average trading volume of 671,280.00 indicating lower market activity. With a market capitalization of $404,279,506.00 the company is classified as a small-cap player and is recognized as a key participant in the Medical - Devices industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its field.
Is ClearPoint Neuro, Inc. (CLPT) a good investment?
Investing in ClearPoint Neuro, Inc. (CLPT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bearish outlook. Always conduct your own research before investing.
What is ClearPoint Neuro, Inc. (CLPT)'s stock forecast?
Analysts predict ClearPoint Neuro, Inc. stock to fluctuate between $9.76 (low) and $30.10 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is ClearPoint Neuro, Inc.'s market capitalization?
As of 2026-02-10, ClearPoint Neuro, Inc.'s market cap is $404,279,506, based on 29,748,308 outstanding shares.
How does ClearPoint Neuro, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, ClearPoint Neuro, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy ClearPoint Neuro, Inc. (CLPT) stock?
To buy ClearPoint Neuro, Inc. (CLPT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CLPT. Place an order (Market, Limit, etc.).
What is the best time to invest in ClearPoint Neuro, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has ClearPoint Neuro, Inc. stock ever split?
ClearPoint Neuro, Inc.'s last stock split was 1:40 on 2016-07-27.
How did ClearPoint Neuro, Inc. perform in the last earnings report?
Revenue: $31,390,000 | EPS: -$0.70 | Growth: -22.22%.
Where can I find ClearPoint Neuro, Inc.'s investor relations reports?
Visit https://www.clearpointneuro.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for ClearPoint Neuro, Inc.?
You can explore historical data from here
What is the all-time high and low for ClearPoint Neuro, Inc. stock?
All-time high: $30.10 (2025-10-09) | All-time low: $4.05 (2023-11-10).
What are the key trends affecting ClearPoint Neuro, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
ClearPoint Neuro is positioned for robust growth in 2026, driven by IRRAS, the PRISM 1.5T system clearance, and the company's new CRO facility. While the immediate future of uniQure's AMT-130 remains unknown, ClearPoint has a large number of drug delivery partners that continue to generate strong data. CLPT's valuation is modest given the company's solid competitive positioning and the step change in revenue that will occur when programs in areas like Parkinson's and epilepsy are commercialized.
benzinga.com
ClearPoint Neuro, Inc. (NASDAQ: CLPT) on Friday said it received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2.
accessnewswire.com
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2. "By achieving CE Mark for the ClearPoint Navigation 3.0.2 software, we are able to unify our global navigation platform which we believe will enable consistent training and hospital IT support," commented Mazin Sabra, Chief Operating Officer at ClearPoint Neuro.
accessnewswire.com
The Company Achieved 20% Comparable Sales Growth in the Fourth Quarter of 2025 at $10.4 Million SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 12, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced preliminary unaudited revenue growth for its fourth quarter of 2025. These preliminary unaudited financial results are management's estimates, are subject to revision in the course of completing annual audit processes, and do not represent a comprehensive statement of the Company's financial results for the period.
accessnewswire.com
Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 20, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it has completed its previously announced acquisition of IRRAS Holdings, Inc. ("IRRAS"). The transaction closed on November 20, 2025 following receipt of IRRAS shareholder approval and satisfaction or waiver of all required closing conditions.
seekingalpha.com
ClearPoint Neuro, Inc. ( CLPT ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Joseph Burnett - President, CEO & Director Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Presentation Operator [Audio Gap] comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, statements related to anticipated industry trends, the company's plans, prospects and strategies, both preliminary and projected, the size of total addressable markets or the market opportunity for the company's products and services, the company's expectation for future development, regulatory approval, timing, commercialization and the market for cell and gene therapies and the anticipated adoption of the company's products and services for use in the delivery of gene and cell therapies, and management's expectations, beliefs, estimates or projections regarding future revenue and results of operations.
zacks.com
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.18 per share a year ago.
seekingalpha.com
ClearPoint Neuro's Q2 results were solid; although real upside is likely to be more apparent from 2026 onward. Key catalysts include the launch of GLP services and partner program commercialization, particularly uniQure's Huntington's therapy. Positive partner data and strong system placements could drive ClearPoint's stock higher in 2025.
seekingalpha.com
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Joseph Michael Burnett - President, CEO & Director Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Anderson Schock - B. Riley Securities, Inc., Research Division Operator Greetings, and welcome to the ClearPoint Neuro, Inc.'s Second Quarter 2025 Financial Results Conference Call.
zacks.com
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.16 per share a year ago.
See all news
